MA49840A - Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) - Google Patents

Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)

Info

Publication number
MA49840A
MA49840A MA049840A MA49840A MA49840A MA 49840 A MA49840 A MA 49840A MA 049840 A MA049840 A MA 049840A MA 49840 A MA49840 A MA 49840A MA 49840 A MA49840 A MA 49840A
Authority
MA
Morocco
Prior art keywords
prmt5
inhibitors
protein arginine
arginine methyltransferase
selective protein
Prior art date
Application number
MA049840A
Other languages
English (en)
French (fr)
Inventor
Michael Hawkins
Hong Lin
Juan Luengo
Rupa Shetty
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Publication of MA49840A publication Critical patent/MA49840A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14Pyrrolo-pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA049840A 2017-08-09 2018-08-09 Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5) MA49840A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762543141P 2017-08-09 2017-08-09
US201862630581P 2018-02-14 2018-02-14
US201862664442P 2018-04-30 2018-04-30

Publications (1)

Publication Number Publication Date
MA49840A true MA49840A (fr) 2020-06-17

Family

ID=63405398

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049840A MA49840A (fr) 2017-08-09 2018-08-09 Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)

Country Status (18)

Country Link
US (4) US10570140B2 (enExample)
EP (2) EP3665179B1 (enExample)
JP (1) JP2020530496A (enExample)
KR (1) KR20200036922A (enExample)
CN (1) CN111527099B (enExample)
AU (1) AU2018313910B2 (enExample)
BR (1) BR112020002736A2 (enExample)
CA (1) CA3072439A1 (enExample)
DK (1) DK3665179T3 (enExample)
ES (1) ES2885180T3 (enExample)
IL (1) IL272519B (enExample)
MA (1) MA49840A (enExample)
MX (1) MX2020001598A (enExample)
PL (1) PL3665179T3 (enExample)
PT (1) PT3665179T (enExample)
UA (1) UA126481C2 (enExample)
WO (1) WO2019032859A1 (enExample)
ZA (1) ZA202000773B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020002736A2 (pt) * 2017-08-09 2020-07-28 Prelude Therapeutics, Incorporated inibidores seletivos da proteína arginina metiltransferase 5 (prmt5)
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
DK3765461T3 (da) * 2018-03-14 2023-11-20 Prelude Therapeutics Inc Selektive protein argininmethyltransferase 5 (prmt5)-hæmmere
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
WO2020033285A1 (en) * 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033288A1 (en) * 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
BR112021015796A2 (pt) * 2019-02-13 2021-10-13 Prelude Therapeutics, Incorporated Inibidor seletivo de proteína arginina metiltransferase 5 (prmt5)
IL318073A (en) * 2019-03-25 2025-02-01 California Inst Of Techn PRMT5 inhibitors and their uses
EP3946352A4 (en) * 2019-04-05 2022-12-28 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5
EP3952874A4 (en) * 2019-04-05 2022-12-28 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5
CA3141855A1 (en) * 2019-05-30 2020-12-03 Angex Pharmaceutical, Inc. Heterocyclic compounds as prmt5 inhibitors
KR20220065811A (ko) * 2019-09-18 2022-05-20 프렐루드 테라퓨틱스, 인코포레이티드 단백질 아르기닌 메틸트랜스퍼라제 5(prmt5)의 선택적 억제제
EP4048674A2 (en) * 2019-10-21 2022-08-31 Accent Therapeutics, Inc. Mettl3 modulators
KR20220086628A (ko) * 2019-10-22 2022-06-23 루핀 리미티드 Prmt5 저해제의 약학적 조합물
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
IL300147A (en) 2020-07-31 2023-03-01 Tango Therapeutics Inc History Piperidin-1-yl-N-pyridin-3-yl-2-oxaacetamide is useful for the treatment of MTAP-deficient and/or MTA-accumulating cancer
JP2023543433A (ja) 2020-09-21 2023-10-16 プレリュード・セラピューティクス・インコーポレイテッド Cdk阻害剤及び医薬としてのその使用
US20220251088A1 (en) * 2020-12-10 2022-08-11 Prelude Therapeutics, Incorporated Processes for Making PRMT5 Inhibitors
TW202233183A (zh) * 2020-12-16 2022-09-01 美商安進公司 新型prmt5抑制劑
JP2023554643A (ja) 2020-12-18 2023-12-28 プレリュード・セラピューティクス・インコーポレイテッド Cdk阻害剤及び医薬としてのその使用
CN117157297A (zh) * 2021-07-20 2023-12-01 上海齐鲁制药研究中心有限公司 Prmt5抑制剂
US20230181589A1 (en) * 2021-12-03 2023-06-15 The Trustees Of Indiana University Prmt5 inhibitors for ocular therapy
US11939340B2 (en) 2022-01-21 2024-03-26 Prelude Therapeutics Incorporated CDK inhibitors and their use as pharmaceuticals
WO2023150612A1 (en) 2022-02-03 2023-08-10 Prelude Therapeutics, Incorporated Cdk inhibitors and their use as pharmaceuticals
WO2023172957A1 (en) 2022-03-09 2023-09-14 Prelude Therapeutics, Incorporated Thaizole-pyrimdiine cdk inhibitors and their use as pharmaceuticals
CA3245813A1 (en) 2022-03-23 2023-09-28 Prelude Therapeutics Inc POLYMORPHIC COMPOUNDS AND THEIR USES
CN116655638B (zh) * 2022-05-12 2024-01-26 上海齐鲁制药研究中心有限公司 氘代prmt5抑制剂
US20240150340A1 (en) 2022-10-06 2024-05-09 Prelude Therapeutics Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
US20240352029A1 (en) 2023-04-14 2024-10-24 Prelude Therapeutics Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
CN116554194A (zh) * 2023-05-23 2023-08-08 江苏八巨药业有限公司 一种卡培他滨中间体的合成方法
WO2025064402A1 (en) * 2023-09-22 2025-03-27 St. Jude Children's Research Hospital, Inc. Method for treating sickle cell disease by targeting senescent cells

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
DE102010060118A1 (de) * 2010-10-22 2012-04-26 Röhm Gmbh Stirnseitenmitnehmer
CA2819625A1 (en) 2010-12-03 2012-06-07 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
AR084824A1 (es) * 2011-01-10 2013-06-26 Intellikine Inc Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
MY199894A (en) * 2012-12-21 2023-11-27 Epizyme Inc Prmt5 inhibitors and uses thereof
EP2970136A1 (en) * 2013-03-14 2016-01-20 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
WO2014145214A2 (en) * 2013-03-15 2014-09-18 Ohio State Innovation Foundation Inhibitors of prmt5 and methods of their use
EP3160466A4 (en) * 2014-06-25 2017-12-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US20170198006A1 (en) * 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3212201B1 (en) 2014-10-28 2022-10-19 BCI Pharma Nucleoside kinase inhibitors
KR101719881B1 (ko) * 2014-12-22 2017-03-24 삼성전기주식회사 렌즈 모듈
TN2017000357A1 (en) * 2015-02-24 2019-01-16 Pfizer Substituted nucleoside derivatives useful as anticancer agents
AR104326A1 (es) * 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI870767B (zh) 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
AU2017230658B2 (en) 2016-03-10 2021-03-04 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as PRMT5 inhibitors
WO2017218802A1 (en) 2016-06-15 2017-12-21 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018075601A1 (en) 2016-10-18 2018-04-26 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018085833A2 (en) 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyl transferase 5 (prmt5)
WO2018085818A1 (en) 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152501A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152548A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
WO2018160855A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018160824A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
BR112020002736A2 (pt) 2017-08-09 2020-07-28 Prelude Therapeutics, Incorporated inibidores seletivos da proteína arginina metiltransferase 5 (prmt5)
US11524962B2 (en) 2017-10-26 2022-12-13 Prelude Therapeutics, Incorporated Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Also Published As

Publication number Publication date
BR112020002736A2 (pt) 2020-07-28
US11208416B2 (en) 2021-12-28
PL3665179T3 (pl) 2021-11-29
JP2020530496A (ja) 2020-10-22
US20190048014A1 (en) 2019-02-14
EP3665179B1 (en) 2021-06-09
WO2019032859A1 (en) 2019-02-14
UA126481C2 (uk) 2022-10-12
US20200148692A1 (en) 2020-05-14
EP3665179A1 (en) 2020-06-17
MX2020001598A (es) 2020-10-28
IL272519B (en) 2022-05-01
DK3665179T3 (da) 2021-08-16
CN111527099B (zh) 2024-03-22
ES2885180T3 (es) 2021-12-13
ZA202000773B (en) 2022-07-27
AU2018313910B2 (en) 2022-12-08
US11078205B2 (en) 2021-08-03
CA3072439A1 (en) 2019-02-14
CN111527099A (zh) 2020-08-11
PT3665179T (pt) 2021-09-10
US20220153747A1 (en) 2022-05-19
US20200361946A1 (en) 2020-11-19
US10570140B2 (en) 2020-02-25
IL272519A (en) 2020-03-31
EP3939986A1 (en) 2022-01-19
AU2018313910A1 (en) 2020-03-05
KR20200036922A (ko) 2020-04-07

Similar Documents

Publication Publication Date Title
MA49840A (fr) Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
MA54543A (fr) Inhibiteurs de kif18a
MA54550A (fr) Inhibiteurs de kif18a
EP3843714A4 (en) CD73 INHIBITORS
EP3952874A4 (en) SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5
EP3833355A4 (en) PRMT5 INHIBITORS
MA52413A (fr) Inhibiteurs de cd73
EP3518934A4 (en) Inhibitors of adenosine 5'-nucleotidase
MA52005A (fr) Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
EP3679031A4 (en) INHIBITORS OF WDR5 PROTEIN PROTEIN BINDING
MA47323A (fr) Protéines de liaison icos
EP3423451A4 (en) INHIBITORS OF WDR5 PROTEIN PROTEIN BINDING
EP3946352A4 (en) SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5
EP3801503A4 (en) INHIBITORS OF SARM1
DK3319939T3 (da) Hydantoin indeholdende deoxyuridintriphosphatase-inhibitorer
EP4063358C0 (en) HISTONE METHYLTRANSFERASE INHIBITORS
EP3706747A4 (en) PRMT5 INHIBITORS
MA52813A (fr) Inhibiteurs de sarm1
MA52809A (fr) Inhibiteurs de sarm1
EP3654875C0 (en) ARTHRODESIS SYSTEM OF A JOINT
EP3817736A4 (en) PIKFYVE INHIBITORS
PL3441706T3 (pl) Układ zamrażający
IL287309A (en) Electrosurgical system
EP3833669A4 (en) PRMT5 INHIBITORS
EP3706742A4 (en) PRMT5 INHIBITORS